Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2019-06-13
2021-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hop Compounds on the Immune System in Overweight People
NCT06745102
Xanthohumol as an Adjuvant Therapy in Critically Ill COVID-19 Patients
NCT05463393
Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)
NCT04790240
Acute Effects of an Herbal Tea on Immune Surveillance and Activation.
NCT04491461
Commercially Available Cannabis Products for Immune Support
NCT05944705
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Participants receive a study drink supplemented with a placebo over a time period of 5 days.
Dietary Intervention 1: Placebo
Participants receive a study drink supplemented with a placebo for 5 days
Xanthohumol
Participants receive a study drink supplemented with Xanthohumol over a time period of 5 days.
Dietary Intervention 2: Xanthohumol and Iso-alpha acids
Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
Iso-alpha acids
Participants receive a study drink supplemented with Iso-alpha acids over a time period of 5 days.
Dietary Intervention 2: Xanthohumol and Iso-alpha acids
Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
Xanthohumol/Iso-alpha acids
Participants receive a study drink supplemented with a combination of Xanthohumol and Iso-alpha acids over a time period of 5 days.
Dietary Intervention 2: Xanthohumol and Iso-alpha acids
Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary Intervention 1: Placebo
Participants receive a study drink supplemented with a placebo for 5 days
Dietary Intervention 2: Xanthohumol and Iso-alpha acids
Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Ina Bergheim
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jung F, Staltner R, Baumann A, Burger K, Halilbasic E, Hellerbrand C, Bergheim I. A Xanthohumol-Rich Hop Extract Diminishes Endotoxin-Induced Activation of TLR4 Signaling in Human Peripheral Blood Mononuclear Cells: A Study in Healthy Women. Int J Mol Sci. 2022 Oct 21;23(20):12702. doi: 10.3390/ijms232012702.
Jung F, Staltner R, Tahir A, Baumann A, Burger K, Halilbasic E, Hellerbrand C, Bergheim I. Oral intake of xanthohumol attenuates lipoteichoic acid-induced inflammatory response in human PBMCs. Eur J Nutr. 2022 Dec;61(8):4155-4166. doi: 10.1007/s00394-022-02964-2. Epub 2022 Jul 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UVienna19a
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.